The molecular genetic background of familial hypercholesterolemia: data from the Slovak nation-wide survey.

Familial hypercholesterolemia (FH) is most frequently caused by LDLR or APOB mutations. Therefore, the aim of our study was to examine the genetic background of Slovak patients suspected of FH. Patients with clinical suspicion of FH (235 unrelated probands and 124 family relatives) were recruited throughout Slovakia during the years 2011-2015. The order of DNA analyses in probands was as follows: 1. APOB mutation p.Arg3527Gln by real-time PCR method, 2. direct sequencing of the LDLR gene 3. MLPA analysis of the LDLR gene. We have identified 14 probands and 2 relatives with an APOB mutation p.Arg3527Gln, and 89 probands and 75 relatives with 54 different LDLR mutations. Nine of LDLR mutations were novel (i.e. p.Asp90Glu, c.314-2A>G, p.Asp136Tyr, p.Ser177Pro, p.Lys225_Glu228delinsCysLys, p.Gly478Glu, p.Gly675Trpfs*42, p.Leu680Pro, p.Thr832Argfs*3). This is the first study on molecular genetics of FH in Slovakia encompassing the analysis of whole LDLR gene. Genetic etiology of FH was confirmed in 103 probands (43.8 %). Out of them, 86.4 % of probands carried the LDLR gene mutation and remaining 13.6 % probands carried the p.Arg3527Gln APOB mutation.

[1]  P. Progias,et al.  Familial Hypercholesterolemia in Greek children and their families: genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum. , 2014, Atherosclerosis.

[2]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[3]  S. Humphries,et al.  Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic , 2013, Atherosclerosis.

[4]  R. Fresa,et al.  Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. , 2013, Atherosclerosis.

[5]  G. Watts,et al.  Genetic analysis of familial hypercholesterolaemia in Western Australia. , 2012, Atherosclerosis.

[6]  B. Ravčuková,et al.  The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations. , 2012, Atherosclerosis.

[7]  N. Cuevas,et al.  Molecular characterization of familial hypercholesterolemia in Spain. , 2012, Atherosclerosis.

[8]  S. Humphries,et al.  Mutation screening in patients for familial hypercholesterolaemia (ADH) , 2010, Clinical genetics.

[9]  E. Sijbrands,et al.  Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. , 2009, Atherosclerosis.

[10]  L. Wsólová,et al.  Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity? , 2007, Atherosclerosis.

[11]  R. Češka,et al.  [Is familial hypercholesterolemia under control in the Czech Republic?]. , 2007, Vnitrni lekarstvi.

[12]  K. Widhalm,et al.  Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations , 2007, Journal of Inherited Metabolic Disease.

[13]  C. Boileau,et al.  Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[14]  M. Trip,et al.  Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. , 2006, European Heart Journal.

[15]  J. Kastelein,et al.  Update of the molecular basis of familial hypercholesterolemia in The Netherlands , 2005, Human mutation.

[16]  E. Ros,et al.  Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene Mutation , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Carolyn M Hutter,et al.  Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.

[18]  M. Pocovi,et al.  Molecular characterization of familial hypercholesterolemia in Spain: Identification of 39 novel and 77 recurrent mutations in LDLR , 2004, Human mutation.

[19]  A. Horvath,et al.  Screening for point mutations in the LDL receptor gene in Bulgarian patients with severe hypercholesterolemia , 2004, Journal of Human Genetics.

[20]  J. Kastelein,et al.  The molecular basis of familial hypercholesterolemia in The Netherlands , 2001, Human Genetics.

[21]  W. März,et al.  Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia , 2001, Human mutation.

[22]  D. Tai,et al.  Identification and haplotype analysis of apolipoprotein B-100 Arg3500-->Trp mutation in hyperlipidemic Chinese. , 1998, Clinical chemistry.

[23]  J. Viikari,et al.  Molecular characterization of minor gene rearrangements in Finnish patients with heterozygous familial hypercholesterolemia: identification of two common missense mutations (Gly823-->Asp and Leu380-->His) and eight rare mutations of the LDL receptor gene. , 1995, American journal of human genetics.

[24]  G. Coetzee,et al.  A missense mutation in the low density lipoprotein receptor gene causes familial hypercholesterolemia in Sephardic Jews , 1993, Human Genetics.

[25]  G. Coetzee,et al.  A common Lithuanian mutation causing familial hypercholesterolemia in Ashkenazi Jews. , 1991, American journal of human genetics.

[26]  P. Kovanen,et al.  Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype. , 1989, The Journal of clinical investigation.

[27]  J. Borén,et al.  [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. , 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[28]  A. Rynkiewicz,et al.  Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrentLDLR mutations , 2010, Journal of Applied Genetics.

[29]  A. Czeizel,et al.  Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary. , 2001, Atherosclerosis.

[30]  V. Gudnason,et al.  Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population , 1997, Human mutation.

[31]  Khachadurian Ak.  Clinical features, diagnosis and frequency of familial hypercholesterolemia. , 1988 .